105 related articles for article (PubMed ID: 19130141)
1. In vitro chemoresistance testing in well-differentiated carcinoid tumors.
Lyons JM; Abergel J; Thomson JL; Anthony CT; Wang YZ; Anthony LB; Boudreaux JP; Strauchen J; Idrees M; Warner RR; Woltering EA
Ann Surg Oncol; 2009 Mar; 16(3):649-55. PubMed ID: 19130141
[TBL] [Abstract][Full Text] [Related]
2. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
[TBL] [Abstract][Full Text] [Related]
4. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
[TBL] [Abstract][Full Text] [Related]
5. [Chemosensitivity test on brain tumors].
Gil-Salú JL; Bosco-López J; Domi Nguez-Villar M; Domínguez-Pascual I; Pérez-Requena J; Palomo MJ; López-Escobar M
Neurocirugia (Astur); 2008 Feb; 19(1):5-11. PubMed ID: 18335150
[TBL] [Abstract][Full Text] [Related]
6. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Lyons JM; Anthony CT; Thomson JL; Woltering EA
Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
[TBL] [Abstract][Full Text] [Related]
7. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.
Larsson R; Nygren P
Anticancer Res; 1993; 13(5C):1825-9. PubMed ID: 8267387
[TBL] [Abstract][Full Text] [Related]
8. Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.
Larsson DE; Lövborg H; Rickardson L; Larsson R; Oberg K; Granberg D
Anticancer Res; 2006; 26(6B):4125-9. PubMed ID: 17201123
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary neuroendocrine/carcinoid tumors: a review article.
Bertino EM; Confer PD; Colonna JE; Ross P; Otterson GA
Cancer; 2009 Oct; 115(19):4434-41. PubMed ID: 19562772
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of the thymidine incorporation assay.
Kern DH; Sondak VK; Morgan CR; Hildebrand-Zanki SU
Ann Clin Lab Sci; 1987; 17(6):383-8. PubMed ID: 3688821
[TBL] [Abstract][Full Text] [Related]
11. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
Scotlandi K; Remondini D; Castellani G; Manara MC; Nardi F; Cantiani L; Francesconi M; Mercuri M; Caccuri AM; Serra M; Knuutila S; Picci P
J Clin Oncol; 2009 May; 27(13):2209-16. PubMed ID: 19307502
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity and chemoresistance testing.
Markman M
J Clin Oncol; 2005 Oct; 23(29):7363-4. PubMed ID: 16210675
[No Abstract] [Full Text] [Related]
14. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.
Sondak VK; Bertelsen CA; Tanigawa N; Hildebrand-Zanki SU; Morton DL; Korn EL; Kern DH
Cancer Res; 1984 Apr; 44(4):1725-8. PubMed ID: 6704978
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitivity and chemoresistance testing in ovarian cancer.
Cree IA
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
[TBL] [Abstract][Full Text] [Related]
16. [In vitro testing for drug resistance and drug sensitivity in clinical oncology].
Kiss I; Zaloudík J; Vyzula R; Tomásek J; Maláska J; Coufal O; Kocáková I
Vnitr Lek; 2001 Sep; 47(9):621-6. PubMed ID: 11715667
[TBL] [Abstract][Full Text] [Related]
17. Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors.
Warren WH; Welker M; Gattuso P
Semin Thorac Cardiovasc Surg; 2006; 18(3):199-205. PubMed ID: 17185179
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
[TBL] [Abstract][Full Text] [Related]
19. Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?
Lippert TH; Ruoff HJ; Volm M
Pharmacology; 2008; 81(3):196-203. PubMed ID: 18176090
[TBL] [Abstract][Full Text] [Related]
20. Cytology of metastatic thymic well-differentiated neuroendocrine carcinoma (thymic carcinoid) in pleural fluid: report of a case.
Cameron SE; Alsharif M; McKeon D; Pambuccian SE
Diagn Cytopathol; 2008 May; 36(5):333-7. PubMed ID: 18418883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
